The pandemic showed us that we need to establish safety and effectiveness across different populations for a universally effective vaccine, including China. And, following Covid-19 development, we noted an instant increase in clinical trials conducted in China. So, why exactly is China an attractive market to consider for drug development strategies?
Company seeks new opportunities for use of mRNA therapeutics.
Just a few years ago, single-cell analyses were complex and not user-friendly. Now, thanks to professionalised workflows, the technology is finding its way into the industry. European Biotechnology spoke with Dr Michael Schnall-Levin, SVP R&D, Founding Scientist, from market leader 10X Genomics about the increasing importance of capturing cell heterogeneity for biomedical research.
Cellex Group is an experienced facility worldwide for all kind of allogeneic and autologous stem cell collections and is, besides that, growing to become a complete service provider for cellular immunotherapy products. One essential area of the portfolio is Cell Community, the perfect solution for researchers in need of cell products.
U.S. government to purchase at not-for-profit price 200 million doses in 2021 and 300 million in the first half of 2022.
New entrants and variants will be main drivers of the COVID-19 vaccine market as supply gradually begins
to catch up with demand.
Advanced therapy medicinal products (ATMPs) are booming, but ATMP formulations are still far from advanced: ATMPs either have a very short shelf life (hours to days) or require (ultra) cold storage conditions. A tailored formulation development program can remarkably improve this situation. Coriolis, an expert for biopharmaceutical research and (formulation) development, expands its ATMP development facilities to meet the increasing market demand.
The cannabis industry has established its first footholds in Europe over the past six years – but what comes next? European Biotechnology invited US-German American consultant, entrepreneur and author Marguerite Arnold to give a long-term future outlook.
Tom Graney, until now CFO of Belgian Oxurion nv, took over from CEO Patrik De Haes. De Haes becomes Non-executive Chairman of the Biopharmaceutical company, spezialised in retinal disorders.
Funding to accelerate clinical progression of Iksuda’s pipeline of new generation of antibody drug conjugates, targeting tumours with high unmet need.